drugset / Trial / NCT00659958

ZAGAL Study: Evaluating Effectiveness and Tolerability of Zonisamide as Adjunctive Therapy in Patients With Partial Onset Seizures Treated With Two Antiepileptic Drugs

NCT00659958

Phase 4 Completed 32 enrolled Eisai Inc. Eisai Farmacêutica S.A. · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to acquire additional information about the appropriate level of dosing of Zonisamide when it is prescribed for patients with partial onset epileptic crisis who are already being treated with two other antiepileptic drugs.

Timeline

Start
2008-04
Primary completion
2009-09
Completion
2009-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Zonisamide Other / unclassified 200 mg
Subject Zonisamide Other / unclassified 300 mg
Subject Zonisamide Other / unclassified 400 mg
Subject Zonisamide Other / unclassified 500 mg

Indications